Health care stocks were falling Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 1.1%.
The iShares Biotechnology ETF (IBB) fell 1.4%.
In corporate news, 23andMe's (ME) customers were asked by New York Attorney General Letitia James to take action for protection of their data as the company goes through bankruptcy, the state prosecutor's office said in a consumer alert Tuesday. 23andMe shares were falling past 13%.
Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. Merck shares were down 4.1%.
Alumis (ALMS) shares rose past 7% after the company and Kaken Pharmaceutical said they signed a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with an option to expand the license to include rheumatological and gastrointestinal diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.